Title: Observational Study on Safety of Long-term Tolvaptan Administration
Abstract: Background: Tolvaptan (TLV), an arginine vasopressin type 2 antagonist, has been widely used in Japan from December 2010 as a treatment for heart failure, but this safety with longer term administration is unknown. Methods: In our hospital, we prescribed TLV to 698 patients from December 2010 to November 2016. In those 698 patients, 83 patients (11.9%) continued taking this drug for more than 3 years. We retrospectively analyzed those 83 patients. Results: The mean age at the start of administration was 76.9 years. 39 patients were men. 24 patients had ischemic heart disease, 26 patients had valvular heart disease, and 41 patients had arrhythmia. 18 patients stopped administration of TLV after taking this drug more than three years. The reasons of stop were as follows: dry mouth accompanied by wearing non-invasive positive pressure ventilation 1, cardiac death 4, non-cardiac death 1, deterioration of general condition due to cancer or high age 5, change of hospital 4, unknown 3. The mean age at the time of death of five deceased cases was 78.6 years. No complications such as dehydration, polyuria, hypernatremia, renal failure and liver failure were observed. Conclusion: In this observational study, the adverse side effect of TLV in patients who continued taking this drug for more than 3 years was only one case of dry mouth.
Publication Year: 2017
Publication Date: 2017-09-20
Language: en
Type: article
Indexed In: ['crossref']
Access and Citation
Cited By Count: 1
AI Researcher Chatbot
Get quick answers to your questions about the article from our AI researcher chatbot